Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC

This study compares lenvatinib (a targeted drug) combined with radioactive seed implants (a radiation technique called I-125 brachytherapy) versus lenvatinib alone for people with liver cancer (HCC) that has stopped responding to TACE (a standard liver-targeted procedure). **You may be eligible if...** - You have liver cancer confirmed by biopsy or clinical criteria - Your liver cancer no longer responds to TACE (called TACE-refractory) based on Japan Society of Hepatology criteria - You have at least one measurable liver tumor - Your liver function is acceptable (Child-Pugh class A or B) - Your performance status is ECOG 0 or 1 and life expectancy is at least 3 months **You may NOT be eligible if...** - Your cancer has spread outside the liver (extrahepatic metastasis) - You have tumor blocking the main portal vein on both sides - You have other serious health conditions (check full eligibility with your doctor) Talk to your doctor to see if this trial is right for you.